Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib

Documenti analoghi

• Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
  di: Romain Aymon, et al.
  Pubblicazione: (2025)
• The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease
  di: Rebecca T. Brooks, et al.
  Pubblicazione: (2024)
• Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
  di: Christina Charles‐Schoeman, et al.
  Pubblicazione: (2024)
• Air Pollution's Hidden Toll: Risks for Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Lung Disease
  di: Sofia Ajeganova, et al.
  Pubblicazione: (2025)
• Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
  di: Zubeyir Salis, et al.
  Pubblicazione: (2026)